# NOTIFICATION OF DEROGATION PURSUANT TO ARTICLE 55(1) OF REGULATION (EU) NO 528/2012

Denmark	
ompetent Authority granting the tempora	ary derogation
Organisation	Email address
Danish Environmental Protection Agency	biocides@mst.dk
case of repeated action: number of prev	ious action(s)
oduct name	
Bright Water	
oduct type	
PT 1	
ativa substance(s)	
etive substance(s)	
Active chlorine released from hypochlorous acid	
rget organism(s)	
Bacteria and virus	
ser category	
Professionals and non-professionals	
outing data of the entire based on Art 54	5 (1) of the DDD
arting date of the action based on Art. 55	o (1) of the BPK
09/06/2020	
nd date of the action based on Art. 55 (1	) of the BPR
06/12/2020	

• Description of danger the derogation is intended to address

<sup>&</sup>lt;sup>1</sup> In this form "Member State" refers to EU Member States, Iceland, Liechtenstein, Norway and Switzerland.

## ☑ danger to public health

The COVID-19 pandemic has caused supply shortage of available products for hygienic hand disinfection. By using derogation 55(1) of 528/2012 to approve active chlorine released from hypochlorous acid more products can be available for this critically needed use during the pandemic.

	1			1 1.1
1 1	dangar	t $\cap$	anımal	haalth
	danger	w	aiiiiiai	псани

(describe briefly the danger, the area affected and the effects of the danger)

#### ☐ danger to environment

(describe briefly the danger, the area affected and the effects of the danger)

### • Geographical area of use

Denmark

#### Absence of any other means to contain the danger

The Danish EPA has been informed that there is a shortage of biocidal products for hand disinfection due to the outbreak of the COVID-19. In order to prevent the spread of vira (and bacteria) and to ensure public health, this product is authorised by derogation, c.f. article 55(1) of the BPR.

#### Limited and controlled use

The authorisation is limited to the 180 days.

#### Applications submitted for the product and/or granted authorisations\*

(applications for authorisation of the product might have been submitted or authorisations might have been granted for this product in other Member States. If so, indicate the relevant product names and reference number(s) in R4BP)

<sup>\*</sup> This section will be removed when publishing the notification in CIRCABC